ATPBD4 Inhibitors
ATP-binding cassette sub-family D member 4 (ATPBD4) inhibitors represent a chemical class designed to interact with the ATPBD4 protein, which is involved in various cellular processes, including the transport of molecules across cellular membranes. ATPBD4 is distinctive for its role in energy utilization and transduction, relying on the hydrolysis of adenosine triphosphate (ATP) to power the conformational changes necessary for substrate transport. Inhibitors in this class are engineered to bind competitively or non-competitively to the ATP-binding sites of the protein, effectively blocking the catalytic activity that is essential for its function. By doing so, these compounds obstruct the protein's normal operation of shuttling essential compounds across the membrane, thereby indirectly affecting the cellular processes that are dependent on this transport mechanism. The design of these inhibitors takes into account the specific structural motifs of ATPBD4 that are involved in ATP binding and hydrolysis, allowing for a precise fit within the active site that leads to the inhibition of its activity.
In terms of the biochemical impact, ATPBD4 inhibitors may also affect the protein's interaction with other cellular partners, considering that protein-protein interactions are often critical for the full functional activity of membrane transporters. The inhibition can result in the stabilization of the protein in an inactive conformation, preventing the normal cycling between different states that are required for transport activity. The effective inhibition of ATPBD4 disrupts the equilibrium of substrate concentrations across membranes, leading to alterations in the concentration gradients that drive various cellular processes. The specificity of these inhibitors lies in their ability to target the ATPBD4 protein without affecting other ATP-binding cassette transporters, ensuring that the disruption is contained to the pathways and processes specifically governed by ATPBD4. The chemical class of ATPBD4 inhibitors thus plays a significant role in modulating the internal cellular environment by controlling a key node in the network of molecular transport.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 indirectly leads to the inhibition of ATPBD4 by preventing the activation of the PI3K/Akt pathway, which is required for the stability and activity of many proteins including ATPBD4. By inhibiting this pathway, LY294002 can reduce the phosphorylation and activity of ATPBD4. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a covalent inhibitor of PI3K. Similar to LY294002, it impedes the PI3K/Akt signaling pathway, which in turn would indirectly inhibit ATPBD4 by destabilizing its phosphorylated state, leading to decreased activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically binds to mTOR (mammalian target of rapamycin) complex and inhibits its activity. Since mTOR signaling is crucial for the regulation of protein synthesis and stability, the inhibition of this pathway can decrease the functional activity of ATPBD4 by reducing its synthesis and stability. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an Akt inhibitor that prevents the activation of Akt and thereby inhibits downstream signaling. This cessation of signaling can reduce the phosphorylation and functionality of ATPBD4, as its activity is dependent on Akt-mediated pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, PD98059 obstructs the MEK/ERK pathway, which may be involved in the phosphorylation and regulation of ATPBD4. This inhibition can lead to a reduction in ATPBD4 activity due to decreased phosphorylation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, SB203580 can hinder the p38 MAPK pathway, potentially decreasing ATPBD4 activity as this protein may be regulated by MAPK-mediated signaling events. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As an inhibitor of JNK, SP600125 may affect the JNK signaling pathway, subsequently leading to reduced activity of ATPBD4 if it is regulated by JNK-mediated phosphorylation. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase (DHODH), an enzyme involved in the de novo synthesis of pyrimidine. By reducing the pyrimidine pool, leflunomide can indirectly lead to decreased synthesis and activity of ATPBD4 as pyrimidine nucleotides are essential for the synthesis of all proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor, Bortezomib can lead to an accumulation of misfolded proteins, inducing stress responses that may downregulate the synthesis of many proteins including ATPBD4, leading to its decreased activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple kinases, including those in the Ras/Raf/MEK/ERK pathway. Inhibition of this pathway can lead to a decrease in ATPBD4 activity if ATPBD4 is regulated by this signaling cascade. | ||||||